{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:58:30Z","timestamp":1788350310011,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["SRD-0120112"],"award-info":[{"award-number":["SRD-0120112"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [<jats:sup>18<\/jats:sup>Fluorine]fluorodeoxyglucose-positron emission tomography ([<jats:sup>18<\/jats:sup>F]FDG-PET) and a\u00a0pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [<jats:sup>18<\/jats:sup>F]FDG-PET disease detection were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 500 patients with HER2\u2009+\u2009EBC screened in the PHERGain trial with a tumor size\u2009&gt;\u20091.5 cm by magnetic resonance imaging (MRI) were included in the RESPONSE substudy. PET[\u2212] criteria entailed the absence of\u2009\u00a0\u2265\u20091 breast lesion with maximum standardized uptake value (SUVmax)\u2009\u2265\u20091.5\u2009\u00d7\u2009SUVmean liver\u2009+\u20092 standard deviation. Among 75 PET[\u2212] patients screened, 21 with SUVmax levels\u2009&lt;\u20092.5 were randomly selected and matched with 21 PET[+] patients with SUVmax levels\u2009\u2265\u20092.5 based on patient characteristics associated with [<jats:sup>18<\/jats:sup>F]FDG-PET status. The association between baseline SUVmax and [<jats:sup>18<\/jats:sup>F]FDG-PET status ([\u2212] or [+]) with clinicopathological characteristics was assessed. In addition, evaluation of stromal tumor-infiltrating lymphocytes (sTILs) and gene expression analysis using PAM50 and Vantage 3D\u2122 Cancer Metabolism Panel were specifically compared in a matched cohort of excluded and enrolled patients based on the [<jats:sup>18<\/jats:sup>F]FDG-PET eligibility criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median SUVmax at baseline was 7.2 (range, 1\u201339.3). Among all analyzed patients, a higher SUVmax was associated with a higher tumor stage, larger tumor size, lymph node involvement, hormone receptor-negative status, higher HER2 protein expression, increased Ki67 proliferation index, and higher histological grade (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). [<jats:sup>18<\/jats:sup>F]FDG-PET [\u2212]\u00a0criteria patients had smaller tumor size (<jats:italic>p<\/jats:italic>\u2009=\u20090.014) along with the absence of lymph node involvement and lower histological grade than [<jats:sup>18<\/jats:sup>F]FDG-PET [+] patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Although no difference in the levels of\u00a0sTILs was found among 42 matched [<jats:sup>18<\/jats:sup>F]FDG-PET [\u2212]\/[+] criteria\u00a0patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.73), [<jats:sup>18<\/jats:sup>F]FDG-PET [\u2212]\u00a0criteria patients showed a decreased risk of recurrence (ROR) and a lower proportion of PAM50 HER2-enriched subtype than [<jats:sup>18<\/jats:sup>F]FDG-PET[+] patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Differences in the expression of genes involved in cancer metabolism were observed between [<jats:sup>18<\/jats:sup>F]FDG-PET [\u2212] and [<jats:sup>18<\/jats:sup>F]FDG-PET[+] criteria\u00a0patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results highlight the clinical, biological, and metabolic heterogeneity of HER2+\u2009breast cancer, which may facilitate the selection of HER2+\u2009EBC patients likely to benefit from [<jats:sup>18<\/jats:sup>F]FDG-PET imaging as a tool to guide therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov; NCT03161353; registration date: May 15, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-024-06683-0","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:02:13Z","timestamp":1712556133000},"page":"2733-2743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-8293","authenticated-orcid":false,"given":"Antonio","family":"Llombart-Cussac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Escriv\u00e0-de-Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Stradella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a Bermejo","family":"de las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Keyaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Garc\u00eda-Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Di Cosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhudit","family":"P\u00e9rez-Escuredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Atienza","family":"de Frutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"6683_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-020-05587-5","volume":"181","author":"MJ Hassett","year":"2020","unstructured":"Hassett MJ, Li H, Burstein HJ, Punglia RS. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020;181:43\u201351. https:\/\/doi.org\/10.1007\/s10549-020-05587-5.","journal-title":"Breast Cancer Res Treat"},{"key":"6683_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","volume":"59","author":"F Schettini","year":"2021","unstructured":"Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021;59:339\u201350. https:\/\/doi.org\/10.1016\/j.breast.2021.07.019.","journal-title":"Breast"},{"key":"6683_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10549-020-05866-1","volume":"184","author":"S Gonz\u00e1lez-Santiago","year":"2020","unstructured":"Gonz\u00e1lez-Santiago S, Saura C, Ciruelos E, et al. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Res Treat. 2020;184:469\u201379. https:\/\/doi.org\/10.1007\/s10549-020-05866-1.","journal-title":"Breast Cancer Res Treat"},{"key":"6683_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026745","volume":"100","author":"MI Lee","year":"2021","unstructured":"Lee MI, Jung YJ, Kim DI, et al. Prognostic value of SUVmax in breast cancer and comparative analyses of molecular subtypes: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100: e26745. https:\/\/doi.org\/10.1097\/MD.0000000000026745.","journal-title":"Medicine (Baltimore)"},{"key":"6683_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda JM, Gebhart G, Ruiz Borrego M, et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021;22:858\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(21)00122-4.","journal-title":"Lancet Oncol"},{"key":"6683_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"key":"6683_CR7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s00259-019-04313-8","volume":"46","author":"L Antunovic","year":"2019","unstructured":"Antunovic L, De Sanctis R, Cozzi L, et al. PET\/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019;46:1468\u201377. https:\/\/doi.org\/10.1007\/s00259-019-04313-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6683_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3389\/fonc.2020.01301","volume":"10","author":"Y Ming","year":"2020","unstructured":"Ming Y, Wu N, Qian T, et al. Progress and future trends in PET\/CT and PET\/MRI molecular imaging approaches for breast cancer. Front Oncol. 2020;10:1301. https:\/\/doi.org\/10.3389\/fonc.2020.01301.","journal-title":"Front Oncol"},{"key":"6683_CR9","doi-asserted-by":"publisher","first-page":"3746232","DOI":"10.1155\/2016\/3746232","volume":"2016","author":"Q Liu","year":"2016","unstructured":"Liu Q, Wang C, Li P, et al. The role of (18)F-FDG PET\/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis. Biomed Res Int. 2016;2016:3746232. https:\/\/doi.org\/10.1155\/2016\/3746232.","journal-title":"Biomed Res Int"},{"key":"6683_CR10","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res"},{"key":"6683_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731148","volume":"11","author":"F Zhao","year":"2021","unstructured":"Zhao F, Huo X, Wang M, et al. Comparing biomarkers for predicting pathological responses to neoadjuvant therapy in HER2-positive breast cancer: a systematic review and meta-analysis. Front Oncol. 2021;11: 731148. https:\/\/doi.org\/10.3389\/fonc.2021.731148.","journal-title":"Front Oncol"},{"key":"6683_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(14)70475-9","volume":"15","author":"B Coudert","year":"2014","unstructured":"Coudert B, Pierga J-Y, Mouret-Reynier M-A, et al. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol. 2014;15:1493\u2013502. https:\/\/doi.org\/10.1016\/S1470-2045(14)70475-9.","journal-title":"Lancet Oncol"},{"key":"6683_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2019.108773","volume":"123","author":"W Murakami","year":"2020","unstructured":"Murakami W, Tozaki M, Sasaki M, et al. Correlation between 18F-FDG uptake on PET\/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol. 2020;123: 108773. https:\/\/doi.org\/10.1016\/j.ejrad.2019.108773.","journal-title":"Eur J Radiol"},{"key":"6683_CR14","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3390\/jcm10143173","volume":"10","author":"M Mori","year":"2021","unstructured":"Mori M, Fujioka T, Kubota K, et al. Relationship between prognostic stage in breast cancer and fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography. J Clin Med. 2021;10:3173. https:\/\/doi.org\/10.3390\/jcm10143173.","journal-title":"J Clin Med"},{"key":"6683_CR15","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/MNM.0000000000000856","volume":"39","author":"E Arslan","year":"2018","unstructured":"Arslan E, \u00c7ermik TF, Trabulus FDC, et al. Role of 18F-FDG PET\/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. Nucl Med Commun. 2018;39:680\u201390. https:\/\/doi.org\/10.1097\/MNM.0000000000000856.","journal-title":"Nucl Med Commun"},{"issue":"Suppl 1","key":"6683_CR16","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, et al. 18F-FDG PET\/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):17S-26S. https:\/\/doi.org\/10.2967\/jnumed.115.157859.","journal-title":"J Nucl Med"},{"key":"6683_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tranon.2018.11.005","volume":"12","author":"A Surov","year":"2019","unstructured":"Surov A, Meyer HJ, Wienke A. Associations between PET parameters and expression of Ki-67 in breast cancer. Transl Oncol. 2019;12:375\u201380. https:\/\/doi.org\/10.1016\/j.tranon.2018.11.005.","journal-title":"Transl Oncol"},{"key":"6683_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s43055-021-00548-4","volume":"52","author":"A AbdElaal","year":"2021","unstructured":"AbdElaal A, Zaher AM, Abdelgawad MI, et al. Correlation of primary tumor metabolic parameters with clinical, histopathological and molecular characteristics in breast cancer patients at pre-operative staging FDG-PET\/CT study. Egypt J Radiol Nucl Med. 2021;52:171.","journal-title":"Egypt J Radiol Nucl Med"},{"key":"6683_CR19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/bjc.2013.469","volume":"109","author":"D Groheux","year":"2013","unstructured":"Groheux D, Giacchetti S, Hatt M, et al. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer. 2013;109:1157\u201364. https:\/\/doi.org\/10.1038\/bjc.2013.469.","journal-title":"Br J Cancer"},{"key":"6683_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40336-021-00426-z","volume":"9","author":"D Groheux","year":"2021","unstructured":"Groheux D, Hindie E. Breast cancer: initial workup and staging with FDG PET\/CT. Clin Transl Imaging. 2021;9:221\u201331. https:\/\/doi.org\/10.1007\/s40336-021-00426-z.","journal-title":"Clin Transl Imaging"},{"key":"6683_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015925","volume":"98","author":"H \u00d6nner","year":"2019","unstructured":"\u00d6nner H, Canaz F, Din\u00e7er M, et al. Which of the fluorine-18 fluorodeoxyglucose positron emission tomography\/computerized tomography parameters are better associated with prognostic factors in breast cancer? Medicine (Baltimore). 2019;98: e15925. https:\/\/doi.org\/10.1097\/MD.0000000000015925.","journal-title":"Medicine (Baltimore)"},{"key":"6683_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti J-L, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426\u201335. https:\/\/doi.org\/10.1007\/s00259-010-1640-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6683_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","volume":"15","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15:1137\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(14)70320-1.","journal-title":"Lancet Oncol"},{"key":"6683_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41523-020-0156-0","volume":"6","author":"Z Kos","year":"2020","unstructured":"Kos Z, Roblin E, Kim RS, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6:17. https:\/\/doi.org\/10.1038\/s41523-020-0156-0.","journal-title":"NPJ Breast Cancer"},{"key":"6683_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","volume":"18","author":"A Llombart-Cussac","year":"2017","unstructured":"Llombart-Cussac A, Cort\u00e9s J, Par\u00e9 L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18:545\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(17)30021-9.","journal-title":"Lancet Oncol"},{"key":"6683_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"O Jh","year":"2016","unstructured":"Jh O, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","journal-title":"Radiology"},{"key":"6683_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18632\/oncotarget.27851","volume":"12","author":"K Kitajima","year":"2021","unstructured":"Kitajima K, Miyoshi Y, Sekine T, et al. Harmonized pretreatment quantitative volume-based FDG-PET\/CT parameters for prognosis of stage I-III breast cancer: multicenter study. Oncotarget. 2021;12:95-105. https:\/\/doi.org\/10.18632\/oncotarget.27851.","journal-title":"Oncotarget"},{"key":"6683_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-018-4981-x","volume":"173","author":"HW Hwang","year":"2019","unstructured":"Hwang HW, Jung H, Hyeon J, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019;173:255\u201366. https:\/\/doi.org\/10.1007\/s10549-018-4981-x.","journal-title":"Breast Cancer Res Treat"},{"key":"6683_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84: 101965. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101965.","journal-title":"Cancer Treat Rev"},{"key":"6683_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","volume":"19","author":"HO Ohnstad","year":"2017","unstructured":"Ohnstad HO, Borgen E, Falk RS, et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res. 2017;19:120. https:\/\/doi.org\/10.1186\/s13058-017-0911-9.","journal-title":"Breast Cancer Res"},{"key":"6683_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-022-00468-0","volume":"22","author":"CE Edmonds","year":"2022","unstructured":"Edmonds CE, O\u2019Brien SR, Mankoff DA, Pantel AR. Novel applications of molecular imaging to guide breast cancer therapy. Cancer Imaging. 2022;22:31. https:\/\/doi.org\/10.1186\/s40644-022-00468-0.","journal-title":"Cancer Imaging"},{"key":"6683_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5603\/NMR.a2016.0043","volume":"20","author":"Y-J Jeong","year":"2017","unstructured":"Jeong Y-J, Jung J-W, Cho Y-Y, et al. Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET\/CT. Nucl Med Rev Cent East Eur. 2017;20:32\u20138. https:\/\/doi.org\/10.5603\/NMR.a2016.0043.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"6683_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1593\/neo.07724","volume":"10","author":"IF Robey","year":"2008","unstructured":"Robey IF, Stephen RM, Brown KS, et al. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 2008;10:745\u201356. https:\/\/doi.org\/10.1593\/neo.07724.","journal-title":"Neoplasia"},{"key":"6683_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/his.13334","volume":"72","author":"R El Ansari","year":"2018","unstructured":"El Ansari R, McIntyre A, Craze ML, et al. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 2018;72:183\u201390. https:\/\/doi.org\/10.1111\/his.13334.","journal-title":"Histopathology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06683-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:02:51Z","timestamp":1720105371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06683-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6683"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06683-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involved human participants and were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments. Approvals from the following regulatory authorities and ethics committees were obtained: Comit\u00e9 de \u00c9tico de la Investigaci\u00f3n con medicamentos del Hospital Arnau de Vilanova (Spain), Comit\u00e9 de Protection des Personnes EST-III H\u00f4pital de Brabois (France), Ethikkommission der Medizinischen Fakult\u00e4t Heidelberg (Germany), The Ethics Committee of the Institut Jules Bordet (Belgium), CEIC\u2014Comissao de Etica para a Investigacao Clinica, Parque Saude Lisboa (Portugal), Fulham Research Ethics Committee Charing Cross Hospital (United Kingdom), and Comitato Etico ASL Brindisi, Comitato Etico della provincia Monza Brianza, Comitato Etico Istituto Europeo di Oncologia e Centro Cardiologico Monzino, Comitato Etico Val Padana, Comitato Etico di Area Vasta Emilia Centro, and Comitati Etico dell\u2019Area Vasta Emilia Nord (Italy).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"A.LC. declares research support (Roche, Agendia, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Gilead, Daichii-Sanyo), a consulting or advisory role (Lilly, Roche, Pfizer, Novartis), speakers\u2019 bureaus (Lilly, AstraZeneca, Merck Sharp & Dohme), travel support (Roche, Pfizer, AstraZeneca), and stock or other ownership (MEDSIR, Initia-Research). A.P. declares lecture fees (Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies & Daiichi Sankyo), advisory role\/consultancy (Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardan Health, Peptomyc & Lilly), leadership role (Reveal Genomics, sl; International Oncology Bureau, sl & 1TrialSP sl), institutional financial interests (Contracted research [Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia inno. Research, SL, Celgene, Astellas & Pzifer], lecture fees [Nanostring technologies] and clinical trials [Boehringer, Lilly, Roche, Novartis, Amgen & Daiichi Sankyo] and leadership roles (Executive boards [SOLTI cooperative group Int. Oncology Bureau & SL, 1TrialSP], patronage committee [SOLTI Foundation & Actitud Frente al C\u00e1ncer Foundation], and co-founder and CSO at Reveal Genomics, SL). J.M.PG. is an employee in MEDSIR and declares advisory role (Lilly, Roche, Eisai, Daichii Sankyo, AstraZeneca, Seattle Genetics, Gilead) and travel expenses (Roche). J.M. declares that he has no conflict of interest. T.P. reports having received fees for non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers\u2019 bureaus; Astra Zeneca, Veracyte, Novartis), consulting fees (e.g., advisory boards; Novartis, Roche), and fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers\u2019 bureaus; Pfizer, Novartis, Astra Zeneca). S.ER. declares consulting or AB (Daiichi Sankyo\/Astra Zeneca; Seagen; Pierre-Fabre), speakers\u2019 bureau (Daiichi Sankyo\/Astra Zeneca; Pfizer; Novartis; Seagen), and research funding (Roche; Synthon; Byondis, medsir; SOLTI; Zymeworks; Daiichi Sankyo\/Astra Zeneca). A.S. declares advisory board (Astra Zeneca, Novartis, Seagen), invited speaker (Daiichi, Novartis, and Boehringer Ingelheim), and travel and accommodations (Eisai, Pfizer, Novartis). M.RB. declares that he has no conflict of interest. B.B.H. declares that she has no conflict of interest. M.K. is a founder, shareholder, and member of the board of directors in Abscint NV\/SA, holds patents related to sdAb imaging and therapy, and has a FWO clinical mandate. P.G. declares that she has no conflict of interest. F.BM. has the HER2DX patent filed and the DNADX patent filed. J.J.GM. declares that he has no conflict of interest. T.G. declares that he has no conflict of interest. M.G. declares honoraria (Roche, Novartis, Gilead, Daiichi-Sankyo) and travel grants and accommodation (Roche, Pfizer, Daiichi-Sankyo). M.SC. declares grants from Medica Scientia Innovation Research (MEDSIR), Syntax for Science, Optimapharm, MD Anderson Cancer Center Madrid, and Ability Pharma that are outside the funding for the submitted work. S.DC. declares speaker\u2019s bureau (AstraZeneca) and AB (Pierre-Fabre; IQVIA; MEDSIR). J.PE. is a full-time employee at MEDSIR. M.A.F. is an employee in Lilly, Spain. J.C. declares consulting\/advisor (Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Expres2ion Biotechnologies), honoraria (Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca), research funding to the institution (Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer Healthcare, Eisai, F.Hoffman-La Roche, Guardant health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London), stock (MedSIR, Nektar Pharmaceuticals, Leuko [relative]), travel, accommodation, expenses (Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead.), and patents: (Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent.Javier Cort\u00e9s Cast\u00e1n, Alejandro Piris Gim\u00e9nez, Violeta Serra Elizalde. WO 2014\/199294 A. ISSUED; Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cort\u00e9s.US 2019\/0338368 A1_LICENSED). G.G. declares that she has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}